Base de dados : MEDLINE
Pesquisa : D02.886.640.074.500.500 [Categoria DeCS]
Referências encontradas : 903 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 91 ir para página                         

  1 / 903 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29466360
[Au] Autor:Kaitu'u-Lino TJ; Brownfoot FC; Beard S; Cannon P; Hastie R; Nguyen TV; Binder NK; Tong S; Hannan NJ
[Ad] Endereço:Translational Obstetrics Group, The Department of Obstetrics and Gynaecology, University of Melbourne and Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
[Ti] Título:Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.
[So] Source:PLoS One;13(2):e0188845, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The discovery of new treatments that prevent or treat preeclampsia would be a major advance. Antiangiogenic factors soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG) are secreted in excess from the placenta, causing hypertension, endothelial dysfunction, and multiorgan injury. We recently identified metformin and esomeprazole as potential treatments for preeclampsia. Both reduce placental and endothelial secretion of sFlt-1 and soluble endoglin, and reduce endothelial dysfunction. OBJECTIVES: We set out to assess whether combining metformin and esomeprazole would additively reduce sFlt-1 and soluble endoglin secretion and reduce endothelial dysfunction (verses drug alone). Metformin and esomeprazole were added to primary placental cells and tissues, and endothelial cells and their effects on sFlt-1 and soluble endoglin secretion were assessed in vitro. Tumor necrosis factor-α (TNF-α) was added to endothelial cells to induce dysfunction in vitro. We examined the ability of metformin + esomeprazole to rescue TNF-α induced vascular cell adhesion molecule-1 (VCAM-1) and Endothelin-1 (ET-1) expression, leukocyte adhesion (markers of endothelial dysfunction). RESULTS: Combining metformin and esomeprazole was additive at reducing sFlt-1 secretion and expression of sFlt-1 e15a mRNA isoform in primary cytotrophoblast, placental explants and endothelial cells. In contrast, no additive reduction in sENG was observed with combined metformin and esomeprazole. The low-dose combination of metformin + esomeprazole additively reduced TNF-α-induced VCAM-1 mRNA, but not VCAM-1 protein expression. There was no additive reduction when combining metformin and esomeprazole on TNF-α induced PBMC adhesion to endothelial cells. However, combining metformin and esomeprazole additively reduced ET-1 mRNA expression. CONCLUSIONS: In conclusion combining metformin and esomeprazole additively reduced secretion of sFlt-1, and markers of endothelial dysfunction. The combination of metformin and esomeprazole may provide a more effective treatment or prevention for preeclampsia compared to either as single agents.
[Mh] Termos MeSH primário: Endotélio Vascular/efeitos dos fármacos
Esomeprazol/administração & dosagem
Metformina/administração & dosagem
Pré-Eclâmpsia/tratamento farmacológico
Receptor 1 de Fatores de Crescimento do Endotélio Vascular/secreção
[Mh] Termos MeSH secundário: Endotélio Vascular/fisiopatologia
Feminino
Células Endoteliais da Veia Umbilical Humana
Seres Humanos
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
9100L32L2N (Metformin); EC 2.7.10.1 (FLT1 protein, human); EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188845


  2 / 903 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29258111
[Au] Autor:Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
[Ad] Endereço:Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
[Ti] Título:Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
[So] Source:Oncology;93 Suppl 1:15-19, 2017.
[Is] ISSN:1423-0232
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Clarithromycin (CAM)-based triple therapy comprising proton pump inhibitors and amoxicillin is administered as first-line eradication treatment against Helicobacter pylori infection. However, the eradication rate achieved with CAM-based triple therapy has decreased to <80% owing to the emergence of CAM-resistant strains. This prospective randomized study aimed to compare the efficacy of CAM-based and metronidazole (MNZ)-based triple therapy in terms of H. pylori eradication. METHODS: H. pylori-positive patients were treated with CAM-based triple therapy comprising esomeprazole and amoxicillin (EAC group) or with MNZ-based triple therapy comprising esomeprazole and amoxicillin (EAM group). RESULTS: H. pylori eradication rates achieved in the intention-to-treat (ITT) and per protocol (PP) analyses were 70.6 and 72.7%, respectively, in the EAC group. Eradication rates obtained via ITT and PP analyses were 91.7 and 94.3%, respectively, in the EAM group. In the EAC group, eradication rates were significantly lower in patients harboring CAM-resistant strains than in those harboring CAM-sensitive strains. In contrast, eradication rates were comparable between patients harboring CAM-resistant strains and those harboring CAM-sensitive strains in the EAM group. CONCLUSION: MNZ-based triple therapy consisting of esomeprazole and amoxicillin is superior to CAM-based triple therapy containing esomeprazole and amoxicillin as first-line eradication treatment against H. pylori.
[Mh] Termos MeSH primário: Claritromicina/uso terapêutico
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori/efeitos dos fármacos
Metronidazol/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Amoxicilina/uso terapêutico
Antibacterianos
Quimioterapia Combinada
Esomeprazol/uso terapêutico
Feminino
Infecções por Helicobacter/microbiologia
Helicobacter pylori/isolamento & purificação
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 140QMO216E (Metronidazole); 804826J2HU (Amoxicillin); H1250JIK0A (Clarithromycin); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171221
[Lr] Data última revisão:
171221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE
[do] DOI:10.1159/000481224


  3 / 903 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953640
[Au] Autor:Li MJ; Li Q; Sun M; Liu LQ
[Ad] Endereço:aSchool of Pharmacy, Shanxi Medical University bDepartment of Pharmacy, The First Hospital of Shanxi Medical University, Taiyuan cDepartment of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan dDepartment of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, P.R. China.
[Ti] Título:Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
[So] Source:Medicine (Baltimore);96(39):e8120, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg. METHODS: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study. RESULTS: For the NMA, eligible RCTs of adults with EE verified by endoscopic examination were randomly assigned to the licensed PPIs at least 4 weeks of continuous therapy. The primary efficacy outcome was the endoscopic healing rates at 4 and 8 weeks. Heartburn relief rates were a secondary efficacy outcome. The rates of withdrawal were analyzed as a safety outcome. In comparison to the common comparator omeprazole 20 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [odds ratio (OR), 1.46 (95% confidence interval, 95% CI, 1.24-1.71)] and 8 weeks [1.58 (1.29-1.92)], and improved the heartburn relief rates [1.29 (1.07-1.56)]. In comparison to lansoprazole 30 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [1.30 (1.10-1.53)] and 8 weeks [1.37 (1.13-1.67)], and improved the heartburn relief rates [1.29 (1.03-1.62)]. In terms of acceptability, only dexlansoprazole 60 mg had significantly more all-cause discontinuation than omeprazole 20 mg [1.54 (1.03-2.29)], pantoprazole 40 mg [1.68 (1.08-2.63)], and lansoprazole 30 mg [1.38 (1.02-1.88)]. CONCLUSION: The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief. Esomeprazole 40 mg, pantoprazole 40 mg, esomeprazole 20 mg, and lansoprazole 30 mg showed more benefits in effectiveness and acceptability than other interventions.
[Mh] Termos MeSH primário: Esofagite Péptica/tratamento farmacológico
Inibidores da Bomba de Prótons/administração & dosagem
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem
Adulto
Pesquisa Comparativa da Efetividade
Dexlansoprazol/administração & dosagem
Esomeprazol/administração & dosagem
Esofagite Péptica/complicações
Feminino
Azia/tratamento farmacológico
Azia/etiologia
Seres Humanos
Lansoprazol/administração & dosagem
Masculino
Meia-Idade
Metanálise em Rede
Omeprazol/administração & dosagem
Rabeprazol/administração & dosagem
Resultado do Tratamento
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 32828355LL (Rabeprazole); D8TST4O562 (pantoprazole); KG60484QX9 (Omeprazole); N3PA6559FT (Esomeprazole); UYE4T5I70X (Dexlansoprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008120


  4 / 903 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28796053
[Au] Autor:Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
[Ad] Endereço:aState Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, bDepartment of Health Statistics, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
[Ti] Título:Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
[So] Source:Medicine (Baltimore);96(32):e7697, 2017 Aug.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Due to increasing antimicrobial resistance, a bismuth-based quadruple regimen has been recommended as an alternative first-line therapy for Helicobacter pylori (H pylori) eradication. However, different results are varied greatly and the availability of bismuth was limited in some countries. We assessed the efficacy and safety of 14-day berberine-containing quadruple therapy as an alternative regimen for H pylori eradication. METHODS: In a randomized, open-label, non-inferiority, phase IV trial between November 25, 2014, and October 15, 2015, 612 treatment-naive patients were randomly assigned to 14-day berberine-containing (n = 308) or 14-day bismuth-containing (n = 304) quadruple therapy. The primary outcomes were eradication rates determined by the C urea breath test (C-UBT) 28 days after the end of treatment. The secondary outcomes were adverse events and compliance. RESULTS: The baseline demographic data including age, gender, body mass index (BMI), general condition and severity score were not statistically different in both groups. The eradication rates in bismuth and berberine groups were 86.4% (266/308) and 90.1% (274/304) in intention-to-treat (ITT) analysis (P = .149), and 89.6% (266/297) and 91.3% (273/299) in per-protocol (PP) analysis (P = .470), respectively. No statistically significant difference was found in the overall incidence of adverse events between both groups (35.7% vs 28.6%, P = .060). CONCLUSIONS: Both regimens achieved the recommended efficacy for H pylori eradication. The berberine-containing quadruple regimen was not inferior to bismuth-containing quadruple regimen and can be recommended as an alternative regimen for H pylori eradication in the local region.
[Mh] Termos MeSH primário: Antiácidos/uso terapêutico
Antibacterianos/uso terapêutico
Berberina/uso terapêutico
Bismuto/uso terapêutico
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Amoxicilina/administração & dosagem
Antiácidos/administração & dosagem
Antiácidos/efeitos adversos
Antibacterianos/administração & dosagem
Antibacterianos/efeitos adversos
Berberina/administração & dosagem
Berberina/efeitos adversos
Bismuto/administração & dosagem
Bismuto/efeitos adversos
Índice de Massa Corporal
Testes Respiratórios
Claritromicina/administração & dosagem
Quimioterapia Combinada
Esomeprazol/administração & dosagem
Feminino
Seres Humanos
Masculino
Meia-Idade
Inibidores da Bomba de Prótons/administração & dosagem
Índice de Gravidade de Doença
Fatores Sexuais
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antacids); 0 (Anti-Bacterial Agents); 0 (Proton Pump Inhibitors); 0I8Y3P32UF (Berberine); 804826J2HU (Amoxicillin); H1250JIK0A (Clarithromycin); N3PA6559FT (Esomeprazole); U015TT5I8H (Bismuth)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170827
[Lr] Data última revisão:
170827
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007697


  5 / 903 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28719375
[Au] Autor:Mah XJ; Gupta V; Loch SN; Ahlenstiel G; Poorten DV
[Ad] Endereço:Department of Gastroenterology and Hepatology, Division of Medicine, University of Sydney at Westmead Hospital, Westmead, New South Wales, Australia.
[Ti] Título:Compounded Levofloxacin Triple Therapy is Safe and Effective for Refractory Helicobacter pylori.
[So] Source:Int J Pharm Compd;21(4):330-333, 2017 Jul-Aug.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Failure of first line and subsequent Helicobacter pylori therapy is a significant problem, as alternate treatments are cumbersome and difficult to access. The purpose of this study was to evaluate the efficacy and safety of a compounded levofloxacin triple therapy in clinical practice as a second or third-line salvage regimen for Helicobacter pylori. Patients referred after first or subsequent treatment failures were prescribed compounded levofloxacin 500 mg, amoxicillin 1 g, and esomeprazole 40 mg, all twice daily for 10 days. Eradication success was determined by 14C-urea breath test or histology at least 4 weeks after completion of therapy. The study included 93 patients, the majority of whom were female (57%) with a mean age of 44. The most common indication for treatment was dyspepsia/risk reduction (84%). Median number of previous treatments was 1 (range: 1 through 6) with treatment used as second line in 83%. Helicobacter pylori eradication was achieved in 89.2% (74/83) per protocol and 79.6% (74/93) on an intention-to-treat basis. Outcome was independent of gender, ethnicity, treatment indication, or number. Treatment was well tolerated, with minor adverse events in 8.4% and only one patient discontinuing therapy. Compounded levofloxacin triple therapy is an effective and safe second line treatment for Helicobacter pylori, with eradication rates comparable to standard levofloxacin-based regimens.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Helicobacter pylori/efeitos dos fármacos
Levofloxacino/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Amoxicilina/administração & dosagem
Antibacterianos/efeitos adversos
Quimioterapia Combinada
Esomeprazol/administração & dosagem
Feminino
Seres Humanos
Levofloxacino/efeitos adversos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 6GNT3Y5LMF (Levofloxacin); 804826J2HU (Amoxicillin); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE


  6 / 903 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28431766
[Au] Autor:Katz PO; Le Moigne A; Pollack C
[Ad] Endereço:Albert Einstein Medical Center, Philadelphia, Pennsylvania. Electronic address: philipokatz@gmail.com.
[Ti] Título:Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg.
[So] Source:Clin Ther;39(5):960-970, 2017 May.
[Is] ISSN:1879-114X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: These secondary analyses used data from 2 similarly designed studies in subjects experiencing frequent heartburn to evaluate the efficacy of esomeprazole 20 mg once daily for 2 weeks, which reflects the approved over-the-counter dosage and duration. METHODS: Subjects without endoscopically identified erosive esophagitis who were experiencing heartburn for ≥6 months and ≥4 of 7 days prior to baseline (study 1, N = 368; study 2, N = 349) were randomly assigned to receive double-blind treatment with esomeprazole 40 or 20 mg (administered as esomeprazole magnesium trihydrate 44.5 and 22.3 mg, respectively) or placebo once daily for 4 weeks. Subjects recorded the severity of heartburn in a daily diary, and investigators assessed subjects at each study visit. Two-week assessments were the primary end points of interest in these analyses and included the percentage of subjects with complete heartburn resolution (no episodes during 7 consecutive days), time to sustained complete heartburn resolution (the first of 7 consecutive episode-free days), and heartburn relief (no episodes other than ≤1 mild episode during 7 consecutive days). FINDINGS: At week 2, the percentages of subjects who experienced complete heartburn resolution were significantly greater with esomeprazole 40 mg (study 1, 26.1%; study 2, 35.3%) and 20 mg (study 1, 25.2%; study 2, 35.7%) compared with placebo (study 1, 9.0%; study 2, 3.4%) (all, P ≤ 0.001). Beginning on day 1, the percentages of subjects who experienced sustained heartburn resolution was significantly greater in the groups treated with esomeprazole 40 mg (study 1, 19%; study 2, 19%; P < 0.0001) and 20 mg (study 1, 10%; study 2, 15%; P < 0.05) compared with the group that received placebo (study 1, 2%; study 2, 1%). Additionally, at week 2, the percentages of subjects experiencing heartburn relief were significantly greater with esomeprazole 40 mg (study 1, 35.3%; study 2, 40.5%) and 20 mg (study 1, 34.5%; study 2, 46.4%) compared with placebo (study 1, 16.5%; study 2, 8.6%) (all, P ≤ 0.001). IMPLICATIONS: The results of this study demonstrate that once-daily treatment with esomeprazole 20 mg for 2 weeks effectively resolved subjects׳ heartburn compared with placebo, beginning on day 1. Studies precede FDA Act 801 clinical trial registration and results submission requirements.
[Mh] Termos MeSH primário: Esomeprazol/uso terapêutico
Azia/tratamento farmacológico
Inibidores da Bomba de Prótons/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Método Duplo-Cego
Esquema de Medicação
Esomeprazol/administração & dosagem
Esofagite Péptica/tratamento farmacológico
Feminino
Seres Humanos
Masculino
Meia-Idade
Inibidores da Bomba de Prótons/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Proton Pump Inhibitors); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170423
[St] Status:MEDLINE


  7 / 903 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28424965
[Au] Autor:Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
[Ad] Endereço:Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936-1080, USA. yvonne.lau@novartis.com.
[Ti] Título:Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
[So] Source:Cancer Chemother Pharmacol;79(6):1119-1128, 2017 Jun.
[Is] ISSN:1432-0843
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The impact of proton pump inhibitors (PPIs) on the pharmacokinetics (PK) and efficacy of ceritinib was evaluated. METHODS: A healthy subject drug-drug interaction (DDI) study was conducted to assess the effect of esomeprazole on the PK of a single 750 mg dose of ceritinib. To further investigate the impact of PPIs on the PK and efficacy of ceritinib in ALK-positive cancer patients, two subgroup analyses were performed. Analysis 1 evaluated ceritinib steady-state trough concentration (C ) and overall response rate (ORR) by concomitant use of PPIs in patients from the ASCEND-1, -2, and -3 studies; analysis 2 evaluated ceritinib single-dose and steady-state AUC and C by concomitant PPI use in patients from ASCEND-1 using a definition of PPI usage similar to that used in the healthy subject study. RESULTS: In the healthy subject study, co-administration of a single 750 mg dose of ceritinib with esomeprazole 40 mg for 6 days decreased ceritinib AUC by 76% and C by 79%. However, based on subgroup analysis 1, patients had similar C and ORR regardless of concomitant PPI usage. Based on analysis 2, co-administration of a single 750 mg ceritinib dose with PPIs for 6 days in patients suggested less effect on ceritinib exposure than that observed in healthy subjects as AUC decreased by 30% and C decreased by 25%. No clinically meaningful effect on steady-state exposure was observed after daily dosing. CONCLUSIONS: Long-term administration of ceritinib with PPIs does not adversely affect the PK and efficacy of ceritinib in ALK-positive cancer patients.
[Mh] Termos MeSH primário: Antineoplásicos/farmacocinética
Carcinoma Pulmonar de Células não Pequenas/complicações
Carcinoma Pulmonar de Células não Pequenas/genética
Esomeprazol/farmacocinética
Neoplasias Pulmonares/complicações
Neoplasias Pulmonares/genética
Inibidores de Proteínas Quinases/farmacocinética
Inibidores da Bomba de Prótons/farmacocinética
Pirimidinas/farmacocinética
Receptores Proteína Tirosina Quinases/genética
Sulfonas/farmacocinética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antineoplásicos/uso terapêutico
Área Sob a Curva
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Interações Medicamentosas
Esomeprazol/uso terapêutico
Feminino
Voluntários Saudáveis
Seres Humanos
Neoplasias Pulmonares/tratamento farmacológico
Masculino
Meia-Idade
Inibidores de Proteínas Quinases/uso terapêutico
Inibidores da Bomba de Prótons/uso terapêutico
Pirimidinas/uso terapêutico
Sulfonas/uso terapêutico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Protein Kinase Inhibitors); 0 (Proton Pump Inhibitors); 0 (Pyrimidines); 0 (Sulfones); EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases); EC 2.7.10.1 (anaplastic lymphoma kinase); K418KG2GET (ceritinib); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.1007/s00280-017-3308-7


  8 / 903 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28407418
[Au] Autor:Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
[Ad] Endereço:College of Veterinary Medicine, Chungnam National University, Yuseong-gu, Daejeon, Korea.
[Ti] Título:Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
[So] Source:J Vet Intern Med;31(3):743-750, 2017 May.
[Is] ISSN:1939-1676
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Esomeprazole is an S-enantiomer of omeprazole that has favorable pharmacokinetics and efficacious acid suppressant properties in humans. However, the pharmacokinetics and effects on intragastric pH of esomeprazole in dogs have not been reported. OBJECTIVE: To determine the pharmacokinetics of esomeprazole administered via various routes (PK study) and to investigate the effect of esomeprazole on intragastric pH with a Bravo pH monitoring system (PD study). ANIMALS: Seven adult male Beagle dogs and 5 adult male Beagle dogs were used for PK and PD study, respectively. METHODS: Both studies used an open, randomized, and crossover design. In the PK study, 7 dogs received intravenous (IV), subcutaneous (SC), and oral doses (PO) of esomeprazole (1 mg/kg). Each treatment period was separated by a washout period of at least 10 days. Esomeprazole plasma concentrations were measured by HPLC/MS/MS. In the efficacy study, intragastric pH was recorded without medication (baseline pH) and following IV, SC, and PO esomeprazole dosing regimens (1 mg/kg) in 5 dogs. RESULTS: The bioavailability of esomeprazole administered as PO enteric-coated granules and as SC injections was 71.4 and 106%, respectively. The half-life was approximately 1 hour. Mean ± SD percent time intragastric pH was ≥3 and ≥4 was 58.9 ± 21.1% and 40.9 ± 17.3% for IV group, 75.8 ± 16.4% and 62.7 ± 17.7% for SC group, 88.2 ± 8.9% and 82.5 ± 7.7% for PO group, and 12.5 ± 3.6% and 3.7 ± 1.8% for baseline. The mean percent time with intragastric pH was ≥3 or ≥4 was significantly increased regardless of the dosing route (P < .05). CONCLUSION: The PK parameters for PO and SC esomeprazole administration were favorable, and esomeprazole significantly increased intragastric pH after IV, PO, and SC administration. IV and SC administration of esomeprazole might be useful when PO administration is not possible. No significant adverse effects were observed.
[Mh] Termos MeSH primário: Antiulcerosos/farmacocinética
Esomeprazol/farmacocinética
[Mh] Termos MeSH secundário: Administração Oral
Animais
Antiulcerosos/administração & dosagem
Antiulcerosos/sangue
Antiulcerosos/farmacologia
Área Sob a Curva
Estudos Cross-Over
Cães
Esomeprazol/administração & dosagem
Esomeprazol/sangue
Esomeprazol/farmacologia
Esôfago/efeitos dos fármacos
Feminino
Concentração de Íons de Hidrogênio/efeitos dos fármacos
Injeções Intravenosas/veterinária
Injeções Subcutâneas/veterinária
Masculino
Valores de Referência
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); N3PA6559FT (Esomeprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1111/jvim.14713


  9 / 903 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28391418
[Au] Autor:Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
[Ad] Endereço:Department of Gastroenterology, Peking University Third Hospital, No 49, North Garden Road, Haidian District, Beijing, 100191, China.
[Ti] Título:Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
[So] Source:Dig Dis Sci;62(6):1580-1589, 2017 Jun.
[Is] ISSN:1573-2568
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The eradication of Helicobacter pylori infection remains a challenge, especially in the patients unsuitable to take penicillin. Cephalosporin has the potential to replace amoxicillin for H. pylori eradication. AIMS: To compare the effectiveness, safety, and compliance of amoxicillin- and cefuroxime-containing quadruple regimens in treatment-naïve patients. METHODS: In this open-label randomized control study, 400 patients with H. pylori infection were divided into amoxicillin-containing (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) or cefuroxime-containing (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, and bismuth 220 mg twice/day for 14 days) quadruple therapy groups. The safety and compliance were assessed 1-3 days after eradication. Urea breath test was performed 8-12 weeks after eradication to determine treatment outcome. RESULTS: The baseline data including antibiotic resistance were well matched between the two groups. The eradication rates between amoxicillin- and cefuroxime-containing quadruple therapy groups were not significantly different [intention-to-treat analysis: 83.5% (95% confidence interval 78.3-88.7%) vs. 81.0% (75.5-86.5%), P = 0.513; modified intention-to-treat analysis: 90.3% (86.0-94.6%) vs. 88.5% (83.9-93.2%), P = 0.586; per-protocol analysis: 91.6% (87.5-95.7%) vs. 89.8% (85.3-94.3%), P = 0.560]. The incidence of adverse effects (18.4 vs. 20.1%, P = 0.678) and compliance (94.7 vs. 94.2%, P = 0.813) were also similar. Variate analyses showed that antibiotic resistance and poor compliance were the independent risk factors for eradication failure. CONCLUSIONS: Esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime achieved similar and relatively satisfactory cure rates, safety, and compliance in first-line H. pylori eradication. Cefuroxime may be a good alternative medicine for eradication instead of amoxicillin for the patients unsuitable to take penicillin.
[Mh] Termos MeSH primário: Antiácidos/uso terapêutico
Antibacterianos/uso terapêutico
Bismuto/uso terapêutico
Esomeprazol/uso terapêutico
Infecções por Helicobacter/tratamento farmacológico
Helicobacter pylori
Inibidores da Bomba de Prótons/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Amoxicilina/uso terapêutico
Antiácidos/efeitos adversos
Antibacterianos/efeitos adversos
Bismuto/efeitos adversos
Testes Respiratórios
Cefuroxima/uso terapêutico
Farmacorresistência Bacteriana
Quimioterapia Combinada/efeitos adversos
Esomeprazol/efeitos adversos
Feminino
Seres Humanos
Análise de Intenção de Tratamento
Levofloxacino/uso terapêutico
Masculino
Adesão à Medicação
Testes de Sensibilidade Microbiana
Meia-Idade
Inibidores da Bomba de Prótons/efeitos adversos
Falha de Tratamento
Ureia/análise
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antacids); 0 (Anti-Bacterial Agents); 0 (Proton Pump Inhibitors); 6GNT3Y5LMF (Levofloxacin); 804826J2HU (Amoxicillin); 8W8T17847W (Urea); N3PA6559FT (Esomeprazole); O1R9FJ93ED (Cefuroxime); U015TT5I8H (Bismuth)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE
[do] DOI:10.1007/s10620-017-4564-4


  10 / 903 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28366568
[Au] Autor:Ragab MA; El-Kimary EI
[Ad] Endereço:Faculty of Pharmacy, Department of Pharmaceutical Analytical Chemistry, University of Alexandria, El-Messalah, Alexandria 21521, Egypt. Electronic address: marmed_2001@yahoo.com.
[Ti] Título:High performance liquid chromatography with photo diode array for separation and analysis of naproxen and esomeprazole in presence of their chiral impurities: Enantiomeric purity determination in tablets.
[So] Source:J Chromatogr A;1497:110-117, 2017 May 12.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A stereoselective high performance liquid chromatographic method with diode array detection (HPLC-DAD) was introduced for S-naproxen and esomeprazole determination in tablets. The separation was achieved on a Kromasil Cellucoat chiral column using a mobile phase consisting of hexane: isopropanol: trifluoroacetic acid (TFA) (90:9.9:0.1 v/v/v). The proposed system was found to be suitable for the enantioseparation of naproxen and omeprazole biologically active isomers. After optimization of the chromatographic conditions, resolution values of 3.84 and 2.17 could be obtained for naproxen and omeprazole isomers, respectively. The method was fully validated for the determination of S-isomers of each drug in their dosage form. Also, the enentiomeric purity was determined in commercial tablet containing S-naproxen and esomeprazole. The enantiomeric purity was calculated for each drug and the chiral impurities (R-isomers) could be determined at 1% level. The method was validated and good results with respect to linearity, precision, accuracy, selectivity and robustness were obtained. The limits of detection (LOD) and quantification (LOQ) were 2.00, 6.50 and 0.10, 0.35µgmL for S-naproxen and esomeprazole, respectively.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão
Esomeprazol/análise
Naproxeno/análise
Comprimidos/química
[Mh] Termos MeSH secundário: 2-Propanol/química
Hexanos/química
Limite de Detecção
Omeprazol/análise
Reprodutibilidade dos Testes
Estereoisomerismo
Ácido Trifluoracético/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hexanes); 0 (Tablets); 57Y76R9ATQ (Naproxen); E5R8Z4G708 (Trifluoroacetic Acid); KG60484QX9 (Omeprazole); N3PA6559FT (Esomeprazole); ND2M416302 (2-Propanol)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170516
[Lr] Data última revisão:
170516
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE



página 1 de 91 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde